Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegozafermin - 89bio

Next Previous
Drug Profile

Pegozafermin - 89bio

Alternative Names: BIO-89-100; TEV 47948

Latest Information Update: 22 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Developer 89bio
  • Class Antihyperlipidaemics; Antineoplastics; Fibroblast growth factors; Hepatoprotectants; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Fibroblast growth factor 21 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypertriglyceridaemia; Non-alcoholic steatohepatitis
  • Phase I/II Non-alcoholic fatty liver disease
  • Preclinical Liver cancer

Most Recent Events

  • 13 Jan 2025 89bio plans to files BLA with US FDA and MAA application with EMA for Hypertriglyceridemia
  • 13 Jan 2025 89bio receives regulatory feedback from the US FDA and the European Medicines Agency (EMA) for pegozafermin on clinical as well as Chemistry, Manufacturing, and Controls (CMC) requirements for marketing authorization filings for Hypertriglyceridemia
  • 13 Jan 2025 89bio completes enrolment in its phase-III ENTRUS Trial for Hypertriglyceridemia in USA, Argentina, Austria, Belgium, Bulgaria, Canada, Chile, Czech Republic, France, Georgia, Germany, Hungary, India, Italy, Latvia, Poland, Puerto Rico, Spain, Mexico and United Kingdom (SC)(NCT05852431)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top